166 related articles for article (PubMed ID: 9261122)
1. Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands.
Turcatti G; Zoffmann S; Lowe JA; Drozda SE; Chassaing G; Schwartz TW; Chollet A
J Biol Chem; 1997 Aug; 272(34):21167-75. PubMed ID: 9261122
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a fluorescent substance P analog.
Tota MR; Daniel S; Sirotina A; Mazina KE; Fong TM; Longmore J; Strader CD
Biochemistry; 1994 Nov; 33(44):13079-86. PubMed ID: 7524660
[TBL] [Abstract][Full Text] [Related]
4. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
5. Probing the binding domain of the NK2 receptor with fluorescent ligands: evidence that heptapeptide agonists and antagonists bind differently.
Turcatti G; Vogel H; Chollet A
Biochemistry; 1995 Mar; 34(12):3972-80. PubMed ID: 7696262
[TBL] [Abstract][Full Text] [Related]
6. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
7. Effect of the non-peptide blocker (+/-) CP 96,345 on the cellular mechanism involved in the response to NK1 receptor stimulation in human skin fibroblasts.
Ziche M; Parenti A; Amerini S; Zawieja D; Maggi CA; Ledda F
Neuropeptides; 1996 Aug; 30(4):345-54. PubMed ID: 8914860
[TBL] [Abstract][Full Text] [Related]
8. Gastric chief cells possess NK1 receptors which mediate pepsinogen secretion and are regulated by agents that increase cAMP and phospholipase C.
Kitsukawa Y; Turner RJ; Pradhan TK; Jensen RT
Biochim Biophys Acta; 1996 Jun; 1312(2):105-16. PubMed ID: 8672532
[TBL] [Abstract][Full Text] [Related]
9. Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
MacDonald D; Silberman SC; Lowe JA; Drozda SE; Leeman SE; Boyd ND
Mol Pharmacol; 1996 May; 49(5):808-13. PubMed ID: 8622630
[TBL] [Abstract][Full Text] [Related]
10. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.
Quartara L; Maggi CA
Neuropeptides; 1997 Dec; 31(6):537-63. PubMed ID: 9574822
[TBL] [Abstract][Full Text] [Related]
11. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
[TBL] [Abstract][Full Text] [Related]
12. Split-receptors in the tachykinin neurokinin-1 system--mutational analysis of intracellular loop 3.
Nielsen SM; Elling CE; Schwartz TW
Eur J Biochem; 1998 Jan; 251(1-2):217-26. PubMed ID: 9492287
[TBL] [Abstract][Full Text] [Related]
13. Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist.
Gether U; Johansen TE; Snider RM; Lowe JA; Nakanishi S; Schwartz TW
Nature; 1993 Mar; 362(6418):345-8. PubMed ID: 7681152
[TBL] [Abstract][Full Text] [Related]
14. A flexible approach to the design of new potent substance P receptor ligands.
Millet R; Goossens L; Bertrand-Caumont K; Goossens JF; Houssin R; Hénichart JP
J Pharm Pharmacol; 2001 Jul; 53(7):929-34. PubMed ID: 11480541
[TBL] [Abstract][Full Text] [Related]
15. Typical and atypical NK1 tachykinin receptor characteristics in the rabbit isolated iris sphincter.
Hall JM; Mitchell D; Morton IK
Br J Pharmacol; 1994 Jul; 112(3):985-91. PubMed ID: 7522864
[TBL] [Abstract][Full Text] [Related]
16. Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429.
Singewald N; Chicchi GG; Thurner CC; Tsao KL; Spetea M; Schmidhammer H; Sreepathi HK; Ferraguti F; Singewald GM; Ebner K
J Neurochem; 2008 Sep; 106(6):2476-88. PubMed ID: 18673452
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification.
Recio R; Vengut-Climent E; Mouillac B; Orcel H; López-Lázaro M; Calderón-Montaño JM; Álvarez E; Khiar N; Fernández I
Eur J Med Chem; 2017 Sep; 138():644-660. PubMed ID: 28710964
[TBL] [Abstract][Full Text] [Related]
18. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.
Rosenkilde MM; Cahir M; Gether U; Hjorth SA; Schwartz TW
J Biol Chem; 1994 Nov; 269(45):28160-4. PubMed ID: 7525569
[TBL] [Abstract][Full Text] [Related]
19. Tachykinin NK1 and NK2 receptors mediate the non-cholinergic bronchospastic response to capsaicin and vagal stimulation in guinea-pigs.
Boni P; Ballati L; Evangelista S
J Auton Pharmacol; 1995 Feb; 15(1):49-54. PubMed ID: 7538136
[TBL] [Abstract][Full Text] [Related]
20. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor.
Holst B; Zoffmann S; Elling CE; Hjorth SA; Schwartz TW
Mol Pharmacol; 1998 Jan; 53(1):166-75. PubMed ID: 9443945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
